The second cycle of negotiations will take place under President Donald Trump's administration. The U.S. government has said ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

European stocks look like newly good investments amid Trump's tariff war and US economic unpredictabilities. European defense stocks are particularly appealing.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

By 2020, Chouinard’s discomfort with his ownership of the lucrative outdoor apparel brand was ramping up. While Patagonia has ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

What Can We Expect From The Fed The Next Few Months? (12:30) - How Should You Position Your Portfolio Right Now? (17:40) - Top Stocks To Keep On Your Watchlist (28:30) - Episode Roundup: ABBV, XOM, ...

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...

Global pharmaceutical companies entering the obesity drug market, currently dominated by Denmark's Novo Nordisk and the United States' Eli Lilly, are introducing new strategies to target market entry.